Cluster composition

Functions

Category	Name	IntersectionWithQuery	PValue	GenesInTerm	GenesInQuery	GenesInTermInQuery	ID
GeneOntologyMolecularFunction	beta-adrenergic receptor kinase activity	GRK2 GRK3	1.49e-05	4	32	2	GO:0047696
GeneOntologyMolecularFunction	G protein-coupled receptor kinase activity	GRK2 GRK3	5.20e-05	7	32	2	GO:0004703
GeneOntologyCellularComponent	beta-catenin-TCF complex	TCF7L2 TCF7L1	1.75e-04	13	32	2	GO:1990907
GeneOntologyCellularComponent	XY body	SCML2 PLK4	5.63e-04	23	32	2	GO:0001741
GeneOntologyCellularComponent	lipid droplet	STARD13 GBF1 VPS13A	7.34e-04	116	32	3	GO:0005811
Domain	CTNNB1-bd_N	TCF7L2 TCF7L1	1.70e-05	4	32	2	IPR013558
Domain	CTNNB1_binding	TCF7L2 TCF7L1	1.70e-05	4	32	2	PF08347
Domain	TCF/LEF	TCF7L2 TCF7L1	1.70e-05	4	32	2	IPR024940
Domain	GPCR_kinase	GRK2 GRK3	5.94e-05	7	32	2	IPR000239
Domain	Catenin_binding_dom	TCF7L2 TCF7L1	1.12e-03	29	32	2	IPR027397
Domain	-	TCF7L2 TCF7L1	1.12e-03	29	32	2	4.10.900.10
Domain	MAGE	MAGEB3 MAGEE1	1.54e-03	34	32	2	SM01373
Domain	RGS	GRK2 GRK3	1.63e-03	35	32	2	PF00615
Domain	RGS	GRK2 GRK3	1.63e-03	35	32	2	SM00315
Domain	RGS	GRK2 GRK3	1.73e-03	36	32	2	PS50132
Domain	MAGE	MAGEB3 MAGEE1	1.73e-03	36	32	2	PS50838
Domain	MHD_dom	MAGEB3 MAGEE1	1.73e-03	36	32	2	IPR002190
Domain	MAGE	MAGEB3 MAGEE1	1.73e-03	36	32	2	PF01454
Domain	RGS	GRK2 GRK3	2.03e-03	39	32	2	IPR016137
Domain	S_TKc	GRK2 GRK3 MYLK PLK4	3.16e-03	359	32	4	SM00220
Domain	PROTEIN_KINASE_ST	GRK2 GRK3 MYLK PLK4	3.25e-03	362	32	4	PS00108
Domain	HMG_box	TCF7L2 TCF7L1	3.71e-03	53	32	2	PF00505
Domain	Protein_kinase_ATP_BS	GRK2 GRK3 MYLK PLK4	3.83e-03	379	32	4	IPR017441
Domain	HMG_BOX_2	TCF7L2 TCF7L1	3.85e-03	54	32	2	PS50118
Domain	HMG	TCF7L2 TCF7L1	3.85e-03	54	32	2	SM00398
Domain	Pkinase	GRK2 GRK3 MYLK PLK4	3.90e-03	381	32	4	PF00069
Domain	-	TCF7L2 TCF7L1	3.99e-03	55	32	2	1.10.30.10
Domain	AGC-kinase_C	GRK2 GRK3	4.13e-03	56	32	2	IPR000961
Domain	AGC_KINASE_CTER	GRK2 GRK3	4.13e-03	56	32	2	PS51285
Domain	S_TK_X	GRK2 GRK3	4.13e-03	56	32	2	SM00133
Domain	HMG_box_dom	TCF7L2 TCF7L1	5.53e-03	65	32	2	IPR009071
Domain	PROTEIN_KINASE_ATP	GRK2 GRK3 MYLK PLK4	7.51e-03	459	32	4	PS00107
Pathway	REACTOME_MITF_M_REGULATED_MELANOCYTE_DEVELOPMENT	LARS1 TCF7L2 TCF7L1	4.32e-05	39	25	3	MM17226
Pathway	REACTOME_RUNX3_REGULATES_WNT_SIGNALING	TCF7L2 TCF7L1	4.51e-05	6	25	2	MM15542
Pathway	KEGG_MEDICUS_PATHOGEN_SALMONELLA_AVRA_TO_BETA_CATENIN_SIGNALING_PATHWAY	TCF7L2 TCF7L1	4.51e-05	6	25	2	M47736
Pathway	KEGG_MEDICUS_PATHOGEN_KSHV_LANA_TO_WNT_SIGNALING_PATHWAY	TCF7L2 TCF7L1	6.31e-05	7	25	2	M47465
Pathway	KEGG_MEDICUS_VARIANT_CDH1_REDUCED_EXPRESSION_TO_BETA_CATENIN_SIGNALING_PATHWAY	TCF7L2 TCF7L1	8.40e-05	8	25	2	M47413
Pathway	REACTOME_REGULATION_OF_MITF_M_DEPENDENT_GENES_INVOLVED_IN_CELL_CYCLE_AND_PROLIFERATION	TCF7L2 TCF7L1	8.40e-05	8	25	2	MM17229
Pathway	REACTOME_RUNX3_REGULATES_WNT_SIGNALING	TCF7L2 TCF7L1	8.40e-05	8	25	2	M27821
Pathway	REACTOME_BINDING_OF_TCF_LEF_CTNNB1_TO_TARGET_GENE_PROMOTERS	TCF7L2 TCF7L1	8.40e-05	8	25	2	M27359
Pathway	KEGG_MEDICUS_VARIANT_MUTATION_INACTIVATED_AXIN_TO_WNT_SIGNALING_PATHWAY	TCF7L2 TCF7L1	1.35e-04	10	25	2	M47486
Pathway	REACTOME_REPRESSION_OF_WNT_TARGET_GENES	TCF7L2 TCF7L1	1.35e-04	10	25	2	MM15156
Pathway	KEGG_MEDICUS_VARIANT_MUTATION_INACTIVATED_APC_TO_WNT_SIGNALING_PATHWAY	TCF7L2 TCF7L1	1.97e-04	12	25	2	M47410
Pathway	REACTOME_REPRESSION_OF_WNT_TARGET_GENES	TCF7L2 TCF7L1	2.71e-04	14	25	2	M27402
Pathway	REACTOME_MITF_M_DEPENDENT_GENE_EXPRESSION	TCF7L2 TCF7L1	3.57e-04	16	25	2	MM17241
Pathway	WP_AMPLIFICATION_AND_EXPANSION_OF_ONCOGENIC_PATHWAYS_AS_METASTATIC_TRAITS	TCF7L2 TCF7L1	4.04e-04	17	25	2	M39443
Pathway	REACTOME_REGULATION_OF_MITF_M_DEPENDENT_GENES_INVOLVED_IN_CELL_CYCLE_AND_PROLIFERATION	TCF7L2 TCF7L1	4.04e-04	17	25	2	M48240
Pathway	REACTOME_FORMATION_OF_THE_BETA_CATENIN_TCF_TRANSACTIVATING_COMPLEX	TCF7L2 TCF7L1	9.56e-04	26	25	2	MM14793
Pathway	KEGG_THYROID_CANCER	TCF7L2 TCF7L1	1.19e-03	29	25	2	M523
Pathway	REACTOME_DEACTIVATION_OF_THE_BETA_CATENIN_TRANSACTIVATING_COMPLEX	TCF7L2 TCF7L1	1.45e-03	32	25	2	MM14975
Pathway	REACTOME_MITF_M_REGULATED_MELANOCYTE_DEVELOPMENT	LARS1 TCF7L2 TCF7L1	1.77e-03	137	25	3	M48232
Pathway	KEGG_MEDICUS_VARIANT_FZD7_OVEREXPRESSION_TO_WNT_SIGNALING_PATHWAY	TCF7L2 TCF7L1	1.94e-03	37	25	2	M47411
Pathway	WP_INFLUENCE_OF_LAMINOPATHIES_ON_WNT_SIGNALING	TCF7L2 TCF7L1	1.94e-03	37	25	2	M39817
Pathway	REACTOME_DEACTIVATION_OF_THE_BETA_CATENIN_TRANSACTIVATING_COMPLEX	TCF7L2 TCF7L1	2.49e-03	42	25	2	M27272
Pathway	WP_HEDGEHOG_SIGNALING_WP4249	GRK2 GRK3	2.61e-03	43	25	2	M39706
Pathway	KEGG_MEDICUS_VARIANT_LRP6_OVEREXPRESSION_TO_WNT_SIGNALING_PATHWAY	TCF7L2 TCF7L1	2.85e-03	45	25	2	M47412
Pathway	KEGG_MEDICUS_REFERENCE_WNT_SIGNALING_PATHWAY	TCF7L2 TCF7L1	2.98e-03	46	25	2	M47409
Pubmed	Cloning of GRK2 cDNA from S49 murine lymphoma cells.	GRK2 GRK3	8.20e-07	2	32	2	8638670
Pubmed	Altered airway and cardiac responses in mice lacking G protein-coupled receptor kinase 3.	GRK2 GRK3	8.20e-07	2	32	2	10198406
Pubmed	Dissecting the roles of GRK2 and GRK3 in μ-opioid receptor internalization and β-arrestin2 recruitment using CRISPR/Cas9-edited HEK293 cells.	GRK2 GRK3	8.20e-07	2	32	2	33060647
Pubmed	G-protein coupled receptor kinase 2 and 3 expression in human detrusor cultured smooth muscle cells.	GRK2 GRK3	8.20e-07	2	32	2	11762794
Pubmed	G protein--coupled receptor kinases.	GRK2 GRK3	8.20e-07	2	32	2	8035170
Pubmed	Restricted high level expression of Tcf-4 protein in intestinal and mammary gland epithelium.	TCF7L2 TCF7L1	8.20e-07	2	32	2	9916915
Pubmed	PLK4 phosphorylation of CP110 is required for efficient centriole assembly.	CCP110 PLK4	8.20e-07	2	32	2	28562169
Pubmed	A gene family of HMG-box transcription factors with homology to TCF-1.	TCF7L2 TCF7L1	8.20e-07	2	32	2	1741298
Pubmed	Human NK cells express CC chemokine receptors 4 and 8 and respond to thymus and activation-regulated chemokine, macrophage-derived chemokine, and I-309.	GRK2 GRK3	2.46e-06	3	32	2	10754297
Pubmed	Wnt/beta-catenin signaling promotes expansion of Isl-1-positive cardiac progenitor cells through regulation of FGF signaling.	TCF7L2 TCF7L1	2.46e-06	3	32	2	17607356
Pubmed	TCF/LEF regulation of the topologically associated domain ADI promotes mESCs to exit the pluripotent ground state.	TCF7L2 TCF7L1	2.46e-06	3	32	2	34525377
Pubmed	Differential effects of CC chemokines on CC chemokine receptor 5 (CCR5) phosphorylation and identification of phosphorylation sites on the CCR5 carboxyl terminus.	GRK2 GRK3	2.46e-06	3	32	2	10085131
Pubmed	A dynamic exchange of TCF3 and TCF4 transcription factors controls MYC expression in colorectal cancer cells.	TCF7L2 TCF7L1	2.46e-06	3	32	2	25659031
Pubmed	Cardiac function in mice overexpressing the beta-adrenergic receptor kinase or a beta ARK inhibitor.	GRK2 GRK3	2.46e-06	3	32	2	7761854
Pubmed	In vivo transcriptional governance of hair follicle stem cells by canonical Wnt regulators.	TCF7L2 TCF7L1	2.46e-06	3	32	2	24463605
Pubmed	The N-termini of GRK2 and GRK3 simulate the stimulating effects of RKIP on β-adrenoceptors.	GRK2 GRK3	2.46e-06	3	32	2	31604529
Pubmed	The Polo kinase Plk4 functions in centriole duplication.	CCP110 PLK4	2.46e-06	3	32	2	16244668
Pubmed	Diverse LEF/TCF Expression in Human Colorectal Cancer Correlates with Altered Wnt-Regulated Transcriptome in a Meta-Analysis of Patient Biopsies.	TCF7L2 TCF7L1	2.46e-06	3	32	2	32403323
Pubmed	TCF-3, 4 protein expression correlates with beta-catenin expression in MSS and MSI-H colorectal cancer from HNPCC patients but not in sporadic colorectal cancers.	TCF7L2 TCF7L1	2.46e-06	3	32	2	20532534
Pubmed	Orphanin FQ/nociceptin-mediated desensitization of opioid receptor-like 1 receptor and mu opioid receptors involves protein kinase C: a molecular mechanism for heterologous cross-talk.	GRK2 GRK3	2.46e-06	3	32	2	12130708
Pubmed	Silencing of long noncoding RNA MYLK-AS1 suppresses nephroblastoma via down-regulation of CCNE1 through transcription factor TCF7L2.	TCF7L2 MYLK	2.46e-06	3	32	2	33438217
Pubmed	A β-catenin-driven switch in TCF/LEF transcription factor binding to DNA target sites promotes commitment of mammalian nephron progenitor cells.	TCF7L2 TCF7L1	4.92e-06	4	32	2	33587034
Pubmed	Essential role of beta-adrenergic receptor kinase 1 in cardiac development and function.	GRK2 GRK3	4.92e-06	4	32	2	8917529
Pubmed	Reduced expression of G protein-coupled receptor kinases in schizophrenia but not in schizoaffective disorder.	GRK2 GRK3	4.92e-06	4	32	2	21784156
Pubmed	Phosphorylation of the type 1A angiotensin II receptor by G protein-coupled receptor kinases and protein kinase C.	GRK2 GRK3	4.92e-06	4	32	2	8662816
Pubmed	Mapping canonical Wnt signaling in the developing and adult retina.	TCF7L2 TCF7L1	4.92e-06	4	32	2	17065530
Pubmed	Hierarchical organization of multi-site phosphorylation at the CXCR4 C terminus.	GRK2 GRK3	4.92e-06	4	32	2	23734232
Pubmed	Phosphorylation of TCF proteins by homeodomain-interacting protein kinase 2.	TCF7L2 TCF7L1	8.19e-06	5	32	2	21285352
Pubmed	Enhanced contractility and decreased beta-adrenergic receptor kinase-1 in mice lacking endogenous norepinephrine and epinephrine.	GRK2 GRK3	8.19e-06	5	32	2	10338466
Pubmed	Plk4-induced centriole biogenesis in human cells.	CCP110 PLK4	8.19e-06	5	32	2	17681131
Pubmed	Dynamic expression and nuclear accumulation of beta-catenin during the development of hair follicle-derived structures.	TCF7L2 TCF7L1	1.23e-05	6	32	2	11731231
Pubmed	beta2-Adrenergic receptor regulation by GIT1, a G protein-coupled receptor kinase-associated ADP ribosylation factor GTPase-activating protein.	GRK2 GRK3	1.23e-05	6	32	2	9826657
Pubmed	Combinatorial depletions of G-protein coupled receptor kinases in immune cells identify pleiotropic and cell type-specific functions.	GRK2 GRK3	1.23e-05	6	32	2	36451830
Pubmed	Two members of the Tcf family implicated in Wnt/beta-catenin signaling during embryogenesis in the mouse.	TCF7L2 TCF7L1	1.23e-05	6	32	2	9488439
Pubmed	Postnatal isoform switch and protein localization of LEF1 and TCF7L2 transcription factors in cortical, thalamic, and mesencephalic regions of the adult mouse brain.	TCF7L2 TCF7L1	1.23e-05	6	32	2	23152144
Pubmed	Dazap2 modulates transcription driven by the Wnt effector TCF-4.	TCF7L2 TCF7L1	1.23e-05	6	32	2	19304756
Pubmed	Function of the cytoplasmic tail of human calcitonin receptor-like receptor in complex with receptor activity-modifying protein 2.	GRK2 GRK3	1.23e-05	6	32	2	20074556
Pubmed	β-catenin and γ-catenin are dispensable for T lymphocytes and AML leukemic stem cells.	TCF7L2 TCF7L1	1.72e-05	7	32	2	32820720
Pubmed	Members of the G protein-coupled receptor kinase family that phosphorylate the beta2-adrenergic receptor facilitate sequestration.	GRK2 GRK3	1.72e-05	7	32	2	8672451
Pubmed	RUNX3 attenuates beta-catenin/T cell factors in intestinal tumorigenesis.	TCF7L2 TCF7L1	1.72e-05	7	32	2	18772112
Pubmed	Determination of bradykinin B2 receptor in vivo phosphorylation sites and their role in receptor function.	GRK2 GRK3	1.72e-05	7	32	2	11517230
Pubmed	Gene expression analysis of canonical Wnt pathway transcriptional regulators during early morphogenesis of the facial region in the mouse embryo.	TCF7L2 TCF7L1	1.72e-05	7	32	2	19303461
Pubmed	SELENOPROTEINS. CRL2 aids elimination of truncated selenoproteins produced by failed UGA/Sec decoding.	FEM1C PRAME	1.72e-05	7	32	2	26138980
Pubmed	Connective tissue fibroblasts and Tcf4 regulate myogenesis.	TCF7L2 TCF7L1	2.29e-05	8	32	2	21177349
Pubmed	TWIST1 Homodimers and Heterodimers Orchestrate Lineage-Specific Differentiation.	TCF7L2 TCF7L1	2.29e-05	8	32	2	32179550
Pubmed	Allelic variants between mouse substrains BALB/cJ and BALB/cByJ influence mononuclear cardiomyocyte composition and cardiomyocyte nuclear ploidy.	ZRSR2P1 SCML2	2.29e-05	8	32	2	32371981
Pubmed	Wnt3a regulates Lef-1 expression during airway submucosal gland morphogenesis.	TCF7L2 TCF7L1	2.94e-05	9	32	2	17335794
Pubmed	Molecular determinants of response kinetics of mouse M1 intrinsically-photosensitive retinal ganglion cells.	GRK2 GRK3	2.94e-05	9	32	2	34873237
Pubmed	Cloning, expression, and chromosomal localization of beta-adrenergic receptor kinase 2. A new member of the receptor kinase family.	GRK2 GRK3	3.67e-05	10	32	2	1869533
Pubmed	A critical role for the Wnt effector Tcf4 in adult intestinal homeostatic self-renewal.	TCF7L2 TCF7L1	3.67e-05	10	32	2	22393260
Pubmed	Expression of Tcf/Lef and sFrp and localization of beta-catenin in the developing mouse lung.	TCF7L2 TCF7L1	4.49e-05	11	32	2	11731265
Pubmed	Tcf7L2 is essential for neurogenesis in the developing mouse neocortex.	TCF7L2 TCF7L1	4.49e-05	11	32	2	29751817
Pubmed	Lbx1 and Tlx3 are opposing switches in determining GABAergic versus glutamatergic transmitter phenotypes.	STMN2 GAD2	5.38e-05	12	32	2	16234809
Pubmed	Redundant and additive functions of the four Lef/Tcf transcription factors in lung epithelial progenitors.	TCF7L2 TCF7L1	5.38e-05	12	32	2	32414917
Pubmed	Hippocampus development and generation of dentate gyrus granule cells is regulated by LEF1.	TCF7L2 TCF7L1	5.38e-05	12	32	2	10631168
Pubmed	A role for mDia, a Rho-regulated actin nucleator, in tangential migration of interneuron precursors.	DIAPH2 GAD2	5.38e-05	12	32	2	22246438
Pubmed	All Tcf HMG box transcription factors interact with Groucho-related co-repressors.	TCF7L2 TCF7L1	5.38e-05	12	32	2	11266540
Pubmed	Tcf3 and Tcf4 are essential for long-term homeostasis of skin epithelia.	TCF7L2 TCF7L1	6.36e-05	13	32	2	19718027
Pubmed	Investigation of genes important in neurodevelopment disorders in adult human brain.	TCF7L2 TCF7L1	6.36e-05	13	32	2	26194112
Pubmed	Orpk mouse model of polycystic kidney disease reveals essential role of primary cilia in pancreatic tissue organization.	TCF7L2 TCF7L1	7.41e-05	14	32	2	15226261
Pubmed	Dose-Dependent and Subset-Specific Regulation of Midbrain Dopaminergic Neuron Differentiation by LEF1-Mediated WNT1/b-Catenin Signaling.	TCF7L2 TCF7L1	7.41e-05	14	32	2	33195246
Pubmed	Wnt3a-/--like phenotype and limb deficiency in Lef1(-/-)Tcf1(-/-) mice.	TCF7L2 TCF7L1	7.41e-05	14	32	2	10090727
Pubmed	Comparative mapping of two adjacent regions of MMU19 with their human counterpart on HSA11q13.	GRK2 AHNAK	8.55e-05	15	32	2	9730611
Pubmed	Canonical Wnt signaling in differentiated osteoblasts controls osteoclast differentiation.	TCF7L2 TCF7L1	8.55e-05	15	32	2	15866165
Pubmed	Phases of canonical Wnt signaling during the development of mouse intestinal epithelium.	TCF7L2 TCF7L1	8.55e-05	15	32	2	17681174
Pubmed	Mutant Lef1 controls Gata6 in sebaceous gland development and cancer.	TCF7L2 TCF7L1	9.76e-05	16	32	2	30886049
Pubmed	Unbiased Identification of trans Regulators of ADAR and A-to-I RNA Editing.	SCML2 AHNAK PES1 WRN	1.09e-04	271	32	4	32433965
Pubmed	Functional genomics identifies therapeutic targets for MYC-driven cancer.	GRK3 MYLK PES1	1.18e-04	103	32	3	22623531
Pubmed	Restriction of Wnt signaling in the dorsal otocyst determines semicircular canal formation in the mouse embryo.	TCF7L2 TCF7L1	1.24e-04	18	32	2	22166339
Pubmed	hnRNPH1 recruits PTBP2 and SRSF3 to modulate alternative splicing in germ cells.	TCF7L2 TCF7L1	1.39e-04	19	32	2	35739118
Pubmed	Wnt/β-catenin signaling in the dental mesenchyme regulates incisor development by regulating Bmp4.	TCF7L2 TCF7L1	1.39e-04	19	32	2	20883686
Pubmed	Function of Wnt/β-catenin in counteracting Tcf3 repression through the Tcf3-β-catenin interaction.	TCF7L2 TCF7L1	1.54e-04	20	32	2	22573616
Pubmed	Sequential roles of Hedgehog and Wnt signaling in osteoblast development.	TCF7L2 TCF7L1	1.54e-04	20	32	2	15576404
Pubmed	Mapping the NPHP-JBTS-MKS protein network reveals ciliopathy disease genes and pathways.	CAB39 CCP110 MAGEE1 FEM1C TCF7L1	1.54e-04	564	32	5	21565611
Pubmed	Tcf7l1 protects the anterior neural fold from adopting the neural crest fate.	TCF7L2 TCF7L1	1.70e-04	21	32	2	27302397
Pubmed	TCF4 deficiency expands ventral diencephalon signaling and increases induction of pituitary progenitors.	TCF7L2 TCF7L1	1.87e-04	22	32	2	17919533
Pubmed	Tcf/Lef repressors differentially regulate Shh-Gli target gene activation thresholds to generate progenitor patterning in the developing CNS.	TCF7L2 TCF7L1	1.87e-04	22	32	2	21775418
Pubmed	Severe defects in dorsal thalamic development in low-density lipoprotein receptor-related protein-6 mutants.	GAD2 TCF7L2	1.87e-04	22	32	2	15342729
Pubmed	Dentate gyrus morphogenesis is regulated by β-catenin function in hem-derived fimbrial glia.	TCF7L2 TCF7L1	2.43e-04	25	32	2	36196585
Pubmed	Obesity-related polymorphisms and their associations with the ability to regulate fat oxidation in obese Europeans: the NUGENOB study.	GAD2 TCF7L2	2.43e-04	25	32	2	19876004
Pubmed	The Wnt effector transcription factor 7-like 2 positively regulates oligodendrocyte differentiation in a manner independent of Wnt/β-catenin signaling.	TCF7L2 TCF7L1	2.63e-04	26	32	2	25810530
Pubmed	Tbx20 acts upstream of Wnt signaling to regulate endocardial cushion formation and valve remodeling during mouse cardiogenesis.	TCF7L2 TCF7L1	2.84e-04	27	32	2	23824573
Pubmed	Distinct adhesion-independent functions of β-catenin control stage-specific sensory neurogenesis and proliferation.	TCF7L2 TCF7L1	2.84e-04	27	32	2	25885041
Pubmed	Genome-wide association study of bipolar disorder accounting for effect of body mass index identifies a new risk allele in TCF7L2.	TCF7L2 RIN2	3.05e-04	28	32	2	24322204
Pubmed	USP7 represses lineage differentiation genes in mouse embryonic stem cells by both catalytic and noncatalytic activities.	STMN2 GAD2 ZRSR2P1 SCML2 MAGEE1	3.52e-04	674	32	5	37196079
Pubmed	SHLD2/FAM35A co-operates with REV7 to coordinate DNA double-strand break repair pathway choice.	LARS1 PES1 WRN	3.56e-04	150	32	3	30154076
Pubmed	Mutation of LRP1 in cardiac neural crest cells causes congenital heart defects by perturbing outflow lengthening.	AHNAK VPS13A	3.75e-04	31	32	2	32546759
Pubmed	Identification of Redox and Glucose-Dependent Txnip Protein Interactions.	SCML2 AHNAK	4.00e-04	32	32	2	27437069
Pubmed	Polycomb-Mediated Repression and Sonic Hedgehog Signaling Interact to Regulate Merkel Cell Specification during Skin Development.	TCF7L2 TCF7L1	4.25e-04	33	32	2	27414999
Pubmed	WDR76 Co-Localizes with Heterochromatin Related Proteins and Rapidly Responds to DNA Damage.	LARS1 SCML2 AHNAK PES1	4.54e-04	394	32	4	27248496
Pubmed	Integrated analysis of Wnt signalling system component gene expression.	TCF7L2 TCF7L1	5.35e-04	37	32	2	35831952
Pubmed	Canonical WNT signaling promotes mammary placode development and is essential for initiation of mammary gland morphogenesis.	TCF7L2 TCF7L1	5.35e-04	37	32	2	15342465
Pubmed	Tissue-specific requirements of beta-catenin in external genitalia development.	TCF7L2 TCF7L1	5.65e-04	38	32	2	18635608
Pubmed	Association study of 182 candidate genes in anorexia nervosa.	GAD2 GRK2 GRK3	6.25e-04	182	32	3	20468064
Pubmed	Bioinformatics and cellular signaling.	CCP110 TCF7L2 MYLK	6.25e-04	182	32	3	15102471
Pubmed	Individual retinal progenitor cells display extensive heterogeneity of gene expression.	TCF7L2 TCF7L1	6.58e-04	41	32	2	18270576
Pubmed	Mouse screen reveals multiple new genes underlying mouse and human hearing loss.	LARS1 STARD13 TCF7L2 GBF1 TCF7L1 VPS13A	8.37e-04	1242	32	6	30973865
Pubmed	LRRC31 inhibits DNA repair and sensitizes breast cancer brain metastasis to radiation therapy.	GBF1 AHNAK WRN	8.46e-04	202	32	3	33005030
Pubmed	Homeodomain-mediated beta-catenin-dependent switching events dictate cell-lineage determination.	TCF7L2 TCF7L1	8.64e-04	47	32	2	16678101
Pubmed	Impaired Spermatogenesis, Muscle, and Erythrocyte Function in U12 Intron Splicing-Defective Zrsr1 Mutant Mice.	DIAPH2 ZRSR2P1	8.64e-04	47	32	2	29617656
Cytoband	22q12.1	GRK3 PES1	2.30e-04	32	32	2	22q12.1
Cytoband	Ensembl 112 genes in cytogenetic band chr5q22	ZRSR2P1 FEM1C	7.86e-04	59	32	2	chr5q22
GeneFamily	MAGE family	MAGEB3 MAGEE1	7.14e-04	40	18	2	1136
GeneFamily	Pleckstrin homology domain containing\|Rho guanine nucleotide exchange factors\|C2 domain containing	GRK2 GRK3	1.75e-02	206	18	2	682
Coexpression	GSE4748_CTRL_VS_LPS_STIM_DC_3H_UP	STARD13 CAB39 MAGEE1 AHNAK RIN2	4.19e-06	200	32	5	M6480
Coexpression	ALFANO_MYC_TARGETS	GAD2 TCF7L2 MYLK PLK4 PES1	9.96e-06	239	32	5	M2477
Coexpression	DACOSTA_UV_RESPONSE_VIA_ERCC3_DN	STARD13 TCF7L2 GBF1 TASOR RIN2 WRN VPS13A	6.37e-05	856	32	7	M4500
Coexpression	GSE3920_UNTREATED_VS_IFNG_TREATED_ENDOTHELIAL_CELL_DN	SLC25A44 GBF1 GRK2 PES1	7.25e-05	184	32	4	M6696
Coexpression	GSE17974_CTRL_VS_ACT_IL4_AND_ANTI_IL12_12H_CD4_TCELL_UP	DIAPH2 OSER1 TCF7L2 AHNAK	8.90e-05	194	32	4	M4192
Coexpression	GSE2405_HEAT_KILLED_VS_LIVE_A_PHAGOCYTOPHILUM_STIM_NEUTROPHIL_9H_DN	CCP110 GRK3 FEM1C WRN	1.00e-04	200	32	4	M6196
Coexpression	GSE4748_CTRL_VS_LPS_AND_CYANOBACTERIUM_LPSLIKE_STIM_DC_3H_UP	OSER1 CAB39 MATN2 RIN2	1.00e-04	200	32	4	M6484
ToppCell	Control-Neu_4\|Control / 5 Neutrophil clusters in COVID-19 patients	DIAPH2 CCP110 GBF1 TASOR VPS13A	2.73e-07	196	32	5	b8b7b54ca17a08fa775507bb22b1c7248ada8f40
ToppCell	droplet-Lung-LUNG-30m-Myeloid-Proliferating_Alveolar_Macrophage\|Lung / Lung_Trachea - method, tissue, subtissue, age, lineage, cell ontology and free annotation	CCP110 SCML2 TCF7L2 PLK4	8.90e-06	184	32	4	16aa8e88bdd51b1d132d5cf33c29963b384a8bae
ToppCell	COVID-19_Mild-dn_T\|COVID-19_Mild / Disease condition and Cell class	MAGEB3 GRK2 GRK3	7.84e-05	116	32	3	79c918f3bebfd5e0b865d2c7673af9ee3bc48779
ToppCell	Control-B_intermediate-1\|World / disease group and sub_cluster of B and Plasma cells(res = 0.5)	GRK2 GRK3 AHNAK	1.49e-04	144	32	3	984470ff6ddce4c743e2db78fa98dae055aaa273
ToppCell	primary_visual_cortex-Neuronal-GABAergic_neuron-Sst-Sst_Myh8_Fibin\|primary_visual_cortex / Per Region, Lineage, Cell class, Cell type, Cell subtype	STARD13 GAD2 MATN2	1.92e-04	157	32	3	741d79c10cb87fa7f14080c6fccb1553c3a20bad
ToppCell	E18.5-samps-Mesenchymal-Matrix_fibroblast-MatrixFB-A\|E18.5-samps / Age Group, Lineage, Cell class and subclass	DIAPH2 GAD2 MYLK	2.18e-04	164	32	3	519ab4fe885dfe4c50846f346a062acc2cb44299
ToppCell	Control-B_intermediate-1\|Control / disease group and sub_cluster of B and Plasma cells(res = 0.5)	GRK2 GRK3 AHNAK	2.30e-04	167	32	3	948504367ecf58144d9dd74d2ec531358fc4b309
ToppCell	facs-Skin-Anagen-24m-Epithelial-bulge_keratinocyte\|Skin / Skin_Bladder_Kidney_Mammary_Gland - method, tissue, subtissue, age, lineage, cell ontology and free annotation	TCF7L2 TCF7L1 MATN2	2.30e-04	167	32	3	78909f685ccd1321064eb0887caf9263e0e54879
ToppCell	droplet-Marrow-nan-24m-Lymphocytic-NK_cell\|Marrow / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation	CAB39 TCF7L2 GRK3	2.34e-04	168	32	3	e979a4fbeb9f21048b47d69e6da75c57650697f2
ToppCell	facs-Marrow-T-cells-3m-Myeloid-promonocyte\|Marrow / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation	DIAPH2 GRK3 AHNAK	2.43e-04	170	32	3	a78d9789c3e7c84a36e1bd380192d7aba4a4d443
ToppCell	facs-Marrow-T-cells-3m-Myeloid-monocyte_+_promonocyte\|Marrow / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation	DIAPH2 GRK3 AHNAK	2.43e-04	170	32	3	ff68600b945b3a5437b14e5411b3db800d0ccbe5
ToppCell	droplet-Heart-nan-3m\|Heart / Tongue_Heart_Limb_Muscle_Aorta_Diaphragm - method, tissue, subtissue, age, lineage, cell ontology and free annotation	TASOR AHNAK RIN2	2.69e-04	176	32	3	749b47eac5436fa34e0d243ffbc6f1897f4e431e
ToppCell	Control\|World / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2	KANSL1L TCF7L1 AHNAK	2.73e-04	177	32	3	b8ff6940e31b749776e81ae4f5bbd577dba9749c
ToppCell	E16.5-Mesenchymal-Mesenchymal_structural-Fibroblastic-AF1-AF1_G2M\|E16.5 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif	DIAPH2 SLC25A44 FEM1C	2.78e-04	178	32	3	c87945146b2734141f07b39d268e0d8086ee0364
ToppCell	facs-Marrow-T-cells-3m-Myeloid\|Marrow / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation	CPA3 TASOR AHNAK	2.91e-04	181	32	3	7286700396676fdc41d9723979b8b408177aceb9
ToppCell	COVID-19_Severe-Classical_Monocyte-cMono_1\|COVID-19_Severe / Disease condition and Cell class	GRK2 GRK3 AHNAK	2.91e-04	181	32	3	0d07a67e8ee3bca687b378afbc4044434e63556d
ToppCell	droplet-Marrow-nan-3m-Myeloid-promonocyte\|Marrow / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation	DIAPH2 GRK3 AHNAK	2.96e-04	182	32	3	bc8d621be57f76d718d9b0f11e023b0f4dcb668d
ToppCell	droplet-Lung-nan-3m-Myeloid-Alveolar_Macrophage\|Lung / Lung_Trachea - method, tissue, subtissue, age, lineage, cell ontology and free annotation	TCF7L2 MATN2 RIN2	3.01e-04	183	32	3	ec3c05b9ce1e0fbb720e0dea41f1e28fd3fd878f
ToppCell	Control-Neu_4\|World / 5 Neutrophil clusters in COVID-19 patients	CCP110 GBF1 VPS13A	3.06e-04	184	32	3	ce7f044956613118ee2e9fb6af2455c3166cb414
ToppCell	COPD-Endothelial-VE_Capillary_A\|COPD / Disease state, Lineage and Cell class	STARD13 MYLK RIN2	3.06e-04	184	32	3	5f4f7775d488ececf086c71441defecbee9d8a9c
ToppCell	droplet-Lung-nan-3m-Myeloid-alveolar_macrophage\|Lung / Lung_Trachea - method, tissue, subtissue, age, lineage, cell ontology and free annotation	TCF7L2 MATN2 RIN2	3.06e-04	184	32	3	3261d767d5e3d9e9fbac22ad73ca14e44beed89c
ToppCell	droplet-Lung-30m-Hematologic-myeloid-alveolar_macrophage-proliferating_alveolar_macrophage\|30m / method, tissue, age, lineage, sublineage, cell ontologies, cell type and subtype	SCML2 TCF7L2 PLK4	3.11e-04	185	32	3	b4af9ae4c358b48357cb135b740266e1652d886a
ToppCell	normal_Pleural_Fluid-Myeloid_cells-Alveolar_Mac\|Myeloid_cells / Location, Cell class and cell subclass	STARD13 KANSL1L TASOR	3.16e-04	186	32	3	701eea0016d69f0f9d29b613948f91239096e6c7
ToppCell	Smart-seq2-blood_(Smart-seq2)-myeloid-myeloid_monocytic-classical_monocyte\|blood_(Smart-seq2) / Per Platform+tissue_group, by lineage_subgroup, cell_group, cell_type	DIAPH2 GRK2 AHNAK	3.16e-04	186	32	3	23b8d51d20b05795a73892d3e20e0f9b6a207820
ToppCell	COPD-Epithelial-ATII\|Epithelial / Disease state, Lineage and Cell class	STARD13 SLC25A44 TCF7L1	3.21e-04	187	32	3	030af361f8bdcd0aff4ec1922702833325cf74d8
ToppCell	Anterior_Cingulate_gyrus_(CgG)-Non-neuronal-Macroglial-Astro-Astrocyte\|Anterior_Cingulate_gyrus_(CgG) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types	TCF7L2 TCF7L1 AHNAK	3.21e-04	187	32	3	dd1d91f101b837bba513f77defa6e6902b2c0570
ToppCell	Anterior_Cingulate_gyrus_(CgG)-Non-neuronal-Macroglial-Astro-Astrocyte-Astro_L1-6_FGFR3_ETNPPL\|Anterior_Cingulate_gyrus_(CgG) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types	TCF7L2 TCF7L1 AHNAK	3.21e-04	187	32	3	4d2115a05ec36dd179ca1d4a525f2d4501aea557
ToppCell	Anterior_Cingulate_gyrus_(CgG)-Non-neuronal-Macroglial-Astro\|Anterior_Cingulate_gyrus_(CgG) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types	TCF7L2 TCF7L1 AHNAK	3.21e-04	187	32	3	ae90c263f80c36a410150d499e268d198944a3d9
ToppCell	facs-Skin-Skin_Anagen-18m-Epithelial-outer_bulge\|Skin / Skin_Bladder_Kidney_Mammary_Gland - method, tissue, subtissue, age, lineage, cell ontology and free annotation	TCF7L2 TCF7L1 MATN2	3.31e-04	189	32	3	d00410010283dc6191ce9857d6c7952678fed588
ToppCell	control-Myeloid-CD14_Monocytes_2\|Myeloid / Cohort 2 (Rhapsody WB + PBMC) with disease condition, lineage and cell classs	TCF7L2 GRK3 AHNAK	3.31e-04	189	32	3	7f78b5bb8195f99b18082cbb612e9199b7a1538c
ToppCell	facs-GAT-Fat-3m\|GAT / Fat_BAT_GAT_MAT_SCAT - method, tissue, subtissue, age, lineage, cell ontology and free annotation	MATN2 AHNAK RIN2	3.36e-04	190	32	3	1d92be1b41cff59e834a9d28868f554bd1f3e471
ToppCell	control-Myeloid-CD14_Monocytes_2\|control / Cohort 2 (Rhapsody WB + PBMC) with disease condition, lineage and cell classs	TCF7L2 GRK3 AHNAK	3.36e-04	190	32	3	47513757e0059e8370e49672a577f25ca842e98c
ToppCell	PBMC-Mild-Myeloid-Classical_Monocyte-Classical_Monocyte-cMono_1\|Mild / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.01)	GRK2 GRK3 AHNAK	3.41e-04	191	32	3	c9f3bdb5c0a90268cab24a0fe4c3a8290fcedeb8
ToppCell	control-Non-classical_Monocyte\|World / Cohort 1 (10x PBMC) with disease condition, cell group and cell class	TCF7L2 GRK2 GRK3	3.41e-04	191	32	3	7122957972f177a1d846d965cef53cfe7568ba54
ToppCell	Anterior_Cingulate_gyrus_(CgG)-Neuronal-Inh_GABAergic-i_Gaba_1-GABA_L1_LAMP5-Inh_L1-4_LAMP5_DUSP4_(Lamp5_Rosehip)\|Anterior_Cingulate_gyrus_(CgG) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types	GAD2 GRK3 RIN2	3.46e-04	192	32	3	63d1b3efe93e5ff939278ebe40bacb38218ea09b
ToppCell	PBMC-Mild-Myeloid-Classical_Monocyte-Classical_Monocyte-cMono_1\|Mild / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.09)	GRK2 GRK3 AHNAK	3.46e-04	192	32	3	b86476037ddf8904c1d8a6b3763af7242c031cf3
ToppCell	Monocytes-Inflammatory_CD16+_macrophages\|World / Immune cells in Kidney/Urine in Lupus Nephritis	TCF7L2 GRK3 RIN2	3.46e-04	192	32	3	4be5c2c946337cd3e710137726358adca563f146
ToppCell	droplet-Pancreas-Endocrine-21m-Epithelial-pancreatic_B_cell\|Pancreas / Large_Intestine_Pancreas_Liver - method, tissue, subtissue, age, lineage, cell ontology and free annotation	GBF1 GRK3 MATN2	3.52e-04	193	32	3	fe451b3295d77b2bd1ac25cf29310c85835a45fe
ToppCell	droplet-Pancreas-Endocrine-21m-Epithelial-pancreatic_B_cell\|Pancreas / Large_Intestine_Pancreas_Liver - method, tissue, subtissue, age, lineage, cell ontology and free annotation	GBF1 GRK3 MATN2	3.52e-04	193	32	3	471e65f02937bc18d7c5facdacdf1df58cf0f839
ToppCell	PBMC-Severe-Myeloid-Classical_Monocyte-Classical_Monocyte-cMono_1\|Severe / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.01)	GRK2 GRK3 AHNAK	3.52e-04	193	32	3	4fb020f11fd7aff06952bfeaabc79b2c7b8873f6
ToppCell	PBMC-Severe-Myeloid-Classical_Monocyte-Classical_Monocyte-cMono_1\|Severe / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.09)	GRK2 GRK3 AHNAK	3.57e-04	194	32	3	885355ebe98e974f841cc59dce3b5228c642c5d0
ToppCell	nucseq-Immune-Immune_Myeloid-pMON-pMON\|nucseq / Celltype signatures by Technology, Lineage, Lineage_subclass, Celltype_group, Cell_type2	TCF7L2 GRK2 GRK3	3.57e-04	194	32	3	e237384b02be460d44eeada3026a5691c66f6fc1
ToppCell	PBMC-Severe-cDC_5\|Severe / Compartment, Disease Groups and Clusters	OSER1 GRK2 FEM1C	3.57e-04	194	32	3	b903e23eb75733ca516770727097fe74a9f8c1d1
ToppCell	nucseq-Immune-Immune_Myeloid-pMON\|nucseq / Celltype signatures by Technology, Lineage, Lineage_subclass, Celltype_group, Cell_type2	TCF7L2 GRK2 GRK3	3.57e-04	194	32	3	0bc83ae79873a5e473e6e1e3111924cd003986a1
ToppCell	droplet-Lung-LUNG-1m-Myeloid-Proliferating_Alveolar_Macrophage\|Lung / Lung_Trachea - method, tissue, subtissue, age, lineage, cell ontology and free annotation	TCF7L2 PLK4 MATN2	3.57e-04	194	32	3	effd38e51062b225ecabc7e1c50154e65495d559
ToppCell	renal_medulla_nuclei-CKD+DKD_normotensive-Mesenchymal-Fibroblast-high_collagen-matrisome_fibroblast-\|CKD+DKD_normotensive / Celltypes from Cells and Nuclei per compartment and clinical group	GRK3 MYLK MATN2	3.62e-04	195	32	3	803f714d91f2d97ecbee8c15a5139fd9310f66c7
ToppCell	Mid-temporal_gyrus_(MTG)-Neuronal-Inh_GABAergic-i_Gaba_1-GABA_L1_LAMP5-Inh_L1-4_LAMP5_DUSP4_(Lamp5_Rosehip)\|Mid-temporal_gyrus_(MTG) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types	GAD2 GRK3 RIN2	3.62e-04	195	32	3	98ca9f3aa36211dde1e6f7f3817b9418c95e583e
ToppCell	severe-Myeloid-CD16_Monocytes\|Myeloid / Cohort 2 (Rhapsody WB + PBMC) with disease condition, lineage and cell classs	TCF7L2 GRK3 AHNAK	3.62e-04	195	32	3	5badcfdeed2fb7453a9c144506ca91c5475cd35f
ToppCell	facs-Pancreas-Endocrine-18m-Epithelial-pancreatic_B_cell\|Pancreas / Large_Intestine_Pancreas_Liver - method, tissue, subtissue, age, lineage, cell ontology and free annotation	GBF1 GRK3 MATN2	3.62e-04	195	32	3	bd8e24dd598990204998d1dd853ba7a53dc0107e
ToppCell	renal_medulla_nuclei-CKD+DKD_normotensive-Mesenchymal-Fibroblast-high_collagen-matrisome_fibroblast\|CKD+DKD_normotensive / Celltypes from Cells and Nuclei per compartment and clinical group	GRK3 MYLK MATN2	3.62e-04	195	32	3	4f70157d42a16ff0259bc24a62803c4df4285c44
ToppCell	Control-Myeloid-ncMonocyte\|Control / Disease state, Lineage and Cell class	TCF7L2 GRK3 RIN2	3.62e-04	195	32	3	fcb05948e7480dc53f06f3fc9b9c3fc129874edd
ToppCell	Control-Myeloid-ncMonocyte\|World / Disease state, Lineage and Cell class	TCF7L2 GRK3 RIN2	3.62e-04	195	32	3	b4444b67a709e82b8e2ee510924c3152cb88b051
ToppCell	Bronchial-NucSeq\|Bronchial / Cell types per location group and 10X technology with lineage, and cell group designations	DIAPH2 STARD13 KANSL1L	3.68e-04	196	32	3	ab53c742866945545a92e2e61850d63c80d9a2a6
ToppCell	ILEUM-non-inflamed-(9)_Neuro_cell\|non-inflamed / shred on tissue, inflammation_status, cell class(v3), cell subclass (v2)	STARD13 MATN2 RIN2	3.68e-04	196	32	3	2b08cd6730119d5dea0152709ab8de580b66cd3c
ToppCell	COVID-19_Mild-Classical_Monocyte-cMono_3\|COVID-19_Mild / Disease condition and Cell class	GRK2 GRK3 AHNAK	3.68e-04	196	32	3	f245e929a286cb097130572e1027b4f01be8b04d
ToppCell	COVID-19_Mild-Classical_Monocyte-cMono_3\|Classical_Monocyte / Disease condition and Cell class	GRK2 GRK3 AHNAK	3.68e-04	196	32	3	15397ec27167bb2fb6fec120b68bf38fc71b2670
ToppCell	10x_3'_v3-blood_(10x_3'_v3)-myeloid-myeloid_monocytic-classical_monocyte\|blood_(10x_3'_v3) / Per Platform+tissue_group, by lineage_subgroup, cell_group, cell_type	DIAPH2 GRK3 AHNAK	3.68e-04	196	32	3	28e9e191361966df3a9bd48450090577aa72a999
ToppCell	ILEUM-non-inflamed-(9)_Enteric_neurons\|non-inflamed / shred on tissue, inflammation_status, cell class(v3), cell subclass (v2)	STARD13 MATN2 RIN2	3.68e-04	196	32	3	998aa523555ed6bc9c1b5cacbf7ba77c7b218e6b
ToppCell	Control-Classical_Monocyte-cMono_2\|Classical_Monocyte / Disease condition and Cell class	GRK2 GRK3 AHNAK	3.73e-04	197	32	3	eb7610c9496a95a5fd866e16abcbc39b83abe617
ToppCell	Tracheal-NucSeq-Epithelial-Epi_submucosal-gland-Myoepithelial\|NucSeq / Cell types per location group and 10X technology with lineage, and cell group designations	MYLK TCF7L1 MATN2	3.73e-04	197	32	3	f0475ad9c09c6da418dba17d3d3c1aaa2ef9ab4e
ToppCell	CF-Myeloid-Monocyte_Macrophage\|Myeloid / Disease state, Lineage and Cell class	STARD13 GRK3 AHNAK	3.73e-04	197	32	3	77b150a987c0a8abe73920d93d69a590ebbbdfea
ToppCell	control-Myeloid-CD16_Monocytes\|Myeloid / Cohort 2 (Rhapsody WB + PBMC) with disease condition, lineage and cell classs	TCF7L2 GRK3 AHNAK	3.73e-04	197	32	3	cdb2866d5a8fbf39847309124479ad49c88852d4
ToppCell	COVID-19_Mild-Classical_Monocyte-cMono_4\|Classical_Monocyte / Disease condition and Cell class	TCF7L2 GRK2 GRK3	3.73e-04	197	32	3	e666f6580e9a20b5e550f02125706db17eec8510
ToppCell	Parenchymal-NucSeq\|Parenchymal / Cell types per location group and 10X technology with lineage, and cell group designations	DIAPH2 STARD13 KANSL1L	3.79e-04	198	32	3	1996373bdccc55aac347d349bd22f6aad6d0c668
ToppCell	Monocytes\|World / Immune cells in Kidney/Urine in Lupus Nephritis	TCF7L2 GRK3 RIN2	3.79e-04	198	32	3	8beccf03c9ec9cd02a96107a9d7ca9a6764c6a61
ToppCell	PBMC-Mild-Myeloid-Classical_Monocyte-Classical_Monocyte-cMono_4\|Mild / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.09)	TCF7L2 GRK3 RIN2	3.79e-04	198	32	3	1ca91559fef231896e16180f5e050155c38f7cfa
ToppCell	mild-Myeloid-CD16_Monocytes\|Myeloid / Cohort 2 (Rhapsody WB + PBMC) with disease condition, lineage and cell classs	TCF7L2 GRK3 AHNAK	3.79e-04	198	32	3	ba97ff6e9d400b53ad013dce54afd7154a0f4fc9
ToppCell	kidney_cells-CKD+DKD_normotensive-Epithelial-Proximal_tubule_epithelial_cell-kidney_proximal_tubule_epithelial_cell-Adaptive_/_Maladaptive_/_Repairing_Proximal_Tubule_Epithelial_Cell\|CKD+DKD_normotensive / Celltypes from Cells and Nuclei per compartment and clinical group	KANSL1L MATN2 AHNAK	3.85e-04	199	32	3	174f6013af6eafa577f84205a62927f2b367fda3
ToppCell	CF-Myeloid-Monocyte_Macrophage\|CF / Disease state, Lineage and Cell class	STARD13 GRK3 AHNAK	3.85e-04	199	32	3	bf95eacb31a4a847350f9d6e95ca76c6b730c400
ToppCell	ILEUM-inflamed-(8)_Fibroblasts\|inflamed / shred on tissue, inflammation_status, cell class(v3), cell subclass (v2)	STMN2 MYLK MATN2	3.85e-04	199	32	3	3a3e2bb21cd0293622b1a975263e918d9ba24265
ToppCell	10x_3'_v3-bone_marrow_(10x_3'_v3)-myeloid-myeloid_monocytic-monocyte\|bone_marrow_(10x_3'_v3) / Per Platform+tissue_group, by lineage_subgroup, cell_group, cell_type	GRK3 AHNAK RIN2	3.85e-04	199	32	3	84879280851380e5bfe6bd48b6bbf57aedf6e003
ToppCell	10x_3'_v3-bone_marrow_(10x_3'_v3)-myeloid-myeloid_monocytic\|bone_marrow_(10x_3'_v3) / Per Platform+tissue_group, by lineage_subgroup, cell_group, cell_type	GRK3 AHNAK RIN2	3.85e-04	199	32	3	7dde5c02fcae64cd2d68f607500f2a46b97851fd
ToppCell	Neuronal-Inhibitory-iA-iA_2(LAMP5)-LCP2--L1-4\|Neuronal / cells hierarchy compared to all cells using T-Statistic	GAD2 GRK3 RIN2	3.90e-04	200	32	3	f268cb1bb047e88913a828614b0a77871f5f8814
ToppCell	severe-Myeloid-CD14_Monocytes_2\|severe / Cohort 2 (Rhapsody WB + PBMC) with disease condition, lineage and cell classs	TCF7L2 GRK3 AHNAK	3.90e-04	200	32	3	27d51fefe914b90e0a16498c43607d52fd38f53c
ToppCell	Neuronal-Inhibitory-iA-iA_2(LAMP5)-LCP2-\|Neuronal / cells hierarchy compared to all cells using T-Statistic	GAD2 GRK3 RIN2	3.90e-04	200	32	3	7345cc7dc24b9174541a3e68ecac8c4c092be400
ToppCell	Fetal_brain-fetalBrain_Zhong_nature-GW10-Stem_cells\|GW10 / Sample Type, Dataset, Time_group, and Cell type.	TCF7L2 PLK4 TCF7L1	3.90e-04	200	32	3	474e6ab48f199315f3cca86b81fdf54e0461b7b8
ToppCell	Control-Control-Myeloid-immature_Neutrophil\|Control / Disease, condition lineage and cell class	CCP110 GBF1 VPS13A	3.90e-04	200	32	3	118321ac443feb42aee171baccfc4610f00a8822
ToppCell	normal_Lung-Fibroblasts-COL14A1+_matrix_FBs\|Fibroblasts / Location, Cell class and cell subclass	SLC25A44 MATN2 AHNAK	3.90e-04	200	32	3	6d8f6a6b3f61c529fbed1376659641030abf4f2c
ToppCell	Neuronal-Inhibitory-iA-iA_2(LAMP5)-LCP2\|Neuronal / cells hierarchy compared to all cells using T-Statistic	GAD2 GRK3 RIN2	3.90e-04	200	32	3	5ff9ac97ef970b3b74ebb07f62a0a1f4176a10b4
ToppCell	Brain_organoid-organoid_Tanaka_cellReport-5w-Neuronal-Intermediate\|5w / Sample Type, Dataset, Time_group, and Cell type.	STMN2 GAD2 GRK3	3.90e-04	200	32	3	c92e4fc0442404481fcac623d691dae6215b852d
ToppCell	Fetal_brain-fetalBrain_Zhong_nature-GW23-Neuronal-GABAergic_neurons\|GW23 / Sample Type, Dataset, Time_group, and Cell type.	STMN2 GAD2 SCML2	3.90e-04	200	32	3	c6bbd33bca86ac7a76a7ba704b3e141237d04549
ToppCell	Control_saline-Mesenchymal_myocytic-Pericyte-Pericyte_2\|Control_saline / Treatment groups by lineage, cell group, cell type	GRK3 MYLK MATN2	3.90e-04	200	32	3	bc8949eb34482aca166c4602ff6ab876cb4c2c3c
ToppCell	Fetal_brain-fetalBrain_Zhong_nature-GW10-Stem_cells-Stem_cells\|GW10 / Sample Type, Dataset, Time_group, and Cell type.	TCF7L2 PLK4 TCF7L1	3.90e-04	200	32	3	01a29651e9bb64ef7666c6a61ec396eeb88b2816
Drug	Mephentermine hemisulfate [1212-72-2]; Down 200; 9.4uM; MCF7; HT_HG-U133A	OSER1 SCML2 FEM1C PLK4 RIN2 WRN VPS13A	9.14e-09	197	32	7	3425_DN
Drug	ionomycin calcium salt; Down 200; 2uM; MCF7; HT_HG-U133A_EA	DIAPH2 OSER1 SCML2 TCF7L2 GRK2 TASOR	3.01e-07	198	32	6	871_DN
Drug	H 85	GRK2 GRK3 MYLK	6.41e-06	26	32	3	CID006439306
Drug	Nitrofural [59-87-0]; Down 200; 20.2uM; MCF7; HT_HG-U133A	DIAPH2 SCML2 TCF7L2 GRK2 VPS13A	7.31e-06	195	32	5	3320_DN
Drug	Mefenamic acid [61-68-7]; Down 200; 16.6uM; PC3; HT_HG-U133A	SCML2 TCF7L2 GBF1 GRK2 VPS13A	7.49e-06	196	32	5	1821_DN
Drug	Naringin hydrate [11032-30-7]; Down 200; 6.6uM; HL60; HT_HG-U133A	SLC25A44 TCF7L2 GRK2 FEM1C AHNAK	7.87e-06	198	32	5	2425_DN
Drug	AASM	LARS1 PES1	1.15e-05	4	32	2	CID000015659
Drug	betaARKct	GRK2 GRK3	2.86e-05	6	32	2	CID000002295
Drug	W2O6	LARS1 PES1	2.86e-05	6	32	2	CID000518557
Drug	NPC 15437	GRK2 GRK3 MYLK	3.67e-05	46	32	3	CID000004548
Drug	I-Q-S	GRK2 GRK3 MYLK PES1	6.57e-05	156	32	4	CID000003540
Drug	SCT-1	GRK2 GRK3	6.85e-05	9	32	2	CID000211458
Drug	dihydrocytochalasin B	GRK2 GRK3 MYLK	7.38e-05	58	32	3	CID000003064
Drug	secalonic acid D	LARS1 CAB39 MYLK	9.46e-05	63	32	3	CID000073431
Drug	geranyl nitrile	GRK2 GRK3	1.48e-04	13	32	2	CID000021768
Drug	DNA-PK Inhibitor III; Up 200; 1uM; MCF7; HT_HG-U133A	STARD13 KANSL1L GRK2 RIN2	1.52e-04	194	32	4	7543_UP
Drug	Anabasine [494-52-0]; Down 200; 24.6uM; MCF7; HT_HG-U133A	DIAPH2 SCML2 TCF7L2 GRK2	1.52e-04	194	32	4	6774_DN
Drug	Iopamidol [60166-93-0]; Up 200; 5.2uM; MCF7; HT_HG-U133A	TCF7L2 GRK2 PLK4 WRN	1.52e-04	194	32	4	7189_UP
Drug	Menadione [58-27-5]; Down 200; 23.2uM; PC3; HT_HG-U133A	STARD13 TCF7L2 TASOR VPS13A	1.52e-04	194	32	4	4662_DN
Drug	Bufexamac [2438-72-4]; Up 200; 18uM; MCF7; HT_HG-U133A	TCF7L2 GRK2 FEM1C PLK4	1.52e-04	194	32	4	7413_UP
Drug	haloperidol; Up 200; 10uM; MCF7; HT_HG-U133A_EA	SCML2 GRK3 PRAME RIN2	1.52e-04	194	32	4	1024_UP
Drug	p,p'-DDA	DIAPH2 GRK2 GRK3	1.53e-04	74	32	3	CID000006730
Drug	Cyclacillin [3485-14-1]; Down 200; 11.8uM; MCF7; HT_HG-U133A	KANSL1L TCF7L2 GRK2 VPS13A	1.55e-04	195	32	4	4358_DN
Drug	prochlorperazine dimaleate salt; Up 200; 10uM; HL60; HT_HG-U133A	STARD13 KANSL1L PLK4 RIN2	1.55e-04	195	32	4	1156_UP
Drug	Phenazopyridine hydrochloride [136-40-3]; Down 200; 16uM; MCF7; HT_HG-U133A	STARD13 SCML2 TCF7L2 GBF1	1.55e-04	195	32	4	6234_DN
Drug	Ethotoin [86-35-1]; Down 200; 19.6uM; MCF7; HT_HG-U133A	TCF7L2 GRK2 PLK4 RIN2	1.55e-04	195	32	4	6052_DN
Drug	Etofenamate [30544-47-9]; Down 200; 10.8uM; MCF7; HT_HG-U133A	DIAPH2 STARD13 SCML2 TCF7L2	1.55e-04	195	32	4	7327_DN
Drug	Catechin-(+,-) hydrate [7295-85-4]; Down 200; 13.8uM; MCF7; HT_HG-U133A	TCF7L2 GRK2 GRK3 RIN2	1.59e-04	196	32	4	3351_DN
Drug	Droperidol [548-73-2]; Down 200; 10.6uM; MCF7; HT_HG-U133A	TCF7L2 GRK3 RIN2 VPS13A	1.59e-04	196	32	4	2645_DN
Drug	Hydrochlorothiazide [58-93-5]; Down 200; 13.4uM; MCF7; HT_HG-U133A	TCF7L2 GBF1 GRK3 RIN2	1.59e-04	196	32	4	1487_DN
Drug	Miconazole [22916-47-8]; Down 200; 9.6uM; MCF7; HT_HG-U133A	TCF7L2 PLK4 RIN2 VPS13A	1.62e-04	197	32	4	1477_DN
Drug	Primidone [125-33-7]; Down 200; 18.4uM; HL60; HT_HG-U133A	DIAPH2 STMN2 MYLK RIN2	1.62e-04	197	32	4	3065_DN
Drug	Pancuronium bromide [15500-66-0]; Down 200; 5.4uM; HL60; HT_HG-U133A	KANSL1L SCML2 TCF7L2 GRK3	1.62e-04	197	32	4	2909_DN
Drug	Anabasine [494-52-0]; Up 200; 24.6uM; HL60; HT_HG-U133A	STARD13 TCF7L2 PLK4 AHNAK	1.62e-04	197	32	4	2512_UP
Drug	Tobramycin [32986-56-4]; Down 200; 8.6uM; HL60; HT_HG-U133A	KANSL1L GRK3 FEM1C PLK4	1.62e-04	197	32	4	2481_DN
Drug	3-Acetylcoumarin [3949-36-8]; Down 200; 21.2uM; HL60; HT_HG-U133A	KANSL1L SLC25A44 PLK4 RIN2	1.62e-04	197	32	4	3044_DN
Drug	estradiol, USP; Up 200; 0.01uM; HL60; HT_HG-U133A	DIAPH2 GAD2 TCF7L2 GRK2	1.65e-04	198	32	4	2701_UP
Drug	Hydroxytacrine maleate (R,S) [118909-22-1]; Down 200; 12.2uM; MCF7; HT_HG-U133A	SCML2 TCF7L2 PLK4 RIN2	1.65e-04	198	32	4	3292_DN
Drug	Betazole hydrochloride; Down 200; 27uM; MCF7; HT_HG-U133A	SLC25A44 TCF7L2 GBF1 GRK2	1.65e-04	198	32	4	1690_DN
Drug	Monensin sodium salt [22373-78-0]; Down 200; 5.8uM; HL60; HT_HG-U133A	KANSL1L GAD2 GRK2 PLK4	1.65e-04	198	32	4	2580_DN
Drug	Chlorhexidine [55-56-1]; Down 200; 8uM; MCF7; HT_HG-U133A	DIAPH2 SLC25A44 TCF7L2 PLK4	1.65e-04	198	32	4	1525_DN
Drug	Bumetanide [28395-03-1]; Up 200; 11uM; PC3; HT_HG-U133A	KANSL1L GAD2 GRK3 PLK4	1.65e-04	198	32	4	5117_UP
Drug	Dienestrol [84-17-3]; Down 200; 15uM; MCF7; HT_HG-U133A	SLC25A44 SCML2 TCF7L2 GRK3	1.65e-04	198	32	4	6208_DN
Drug	Naloxone hydrochloride [357-08-4]; Up 200; 11uM; PC3; HG-U133A	SLC25A44 GBF1 PRAME PES1	1.65e-04	198	32	4	1924_UP
Drug	Ceftazidime pentahydrate [78439-06-2]; Down 200; 6.2uM; MCF7; HT_HG-U133A	DIAPH2 STARD13 TCF7L2 GRK3	1.68e-04	199	32	4	5473_DN
Drug	Captopril [62571-86-2]; Down 200; 17.2uM; MCF7; HT_HG-U133A	TCF7L2 GBF1 GRK2 PLK4	1.68e-04	199	32	4	1488_DN
Drug	Cefazolin sodium salt [27164-46-1]; Down 200; 8.4uM; HL60; HT_HG-U133A	GAD2 TCF7L2 GRK2 PLK4	1.68e-04	199	32	4	2564_DN
Drug	Midodrine hydrochloride [3092-17-9]; Down 200; 13.8uM; MCF7; HT_HG-U133A	SCML2 TCF7L2 PLK4 RIN2	1.68e-04	199	32	4	6804_DN
Drug	Coralyne chloride hydrate [38989-38-7]; Up 200; 9.6uM; MCF7; HT_HG-U133A	KANSL1L GRK2 FEM1C PLK4	1.68e-04	199	32	4	2652_UP
Drug	Tyloxapol [25301-02-4]; Down 200; 4uM; HL60; HT_HG-U133A	SLC25A44 TCF7L2 FEM1C PES1	1.68e-04	199	32	4	3074_DN
Drug	Estriol [50-27-1]; Up 200; 13.8uM; HL60; HT_HG-U133A	STARD13 TCF7L1 MATN2 AHNAK	1.71e-04	200	32	4	6140_UP
Drug	clozapine; Down 200; 10uM; MCF7; HT_HG-U133A	DIAPH2 TCF7L2 GRK3 PLK4	1.71e-04	200	32	4	6947_DN
Drug	Suramin sodium salt; Up 200; 10uM; PC3; HT_HG-U133A	TCF7L2 GRK3 AHNAK VPS13A	1.71e-04	200	32	4	7501_UP
Drug	Edrophonium chloride [116-38-1]; Down 200; 19.8uM; MCF7; HT_HG-U133A	SLC25A44 TCF7L2 GRK3 PLK4	1.71e-04	200	32	4	1519_DN
Drug	Carbamazepine [298-46-4]; Up 200; 17uM; MCF7; HT_HG-U133A	TCF7L2 GRK2 PLK4 AHNAK	1.71e-04	200	32	4	1683_UP
Drug	8-N3cAMP	GRK2 GRK3	1.72e-04	14	32	2	CID006426627
Drug	8-(6-aminohexyl)amino cyclic AMP	GRK2 GRK3	1.72e-04	14	32	2	CID000161999
Drug	NA-382	GRK2 GRK3	1.99e-04	15	32	2	CID000132534
Drug	fluphenazine-N-mustard	GAD2 MYLK	2.27e-04	16	32	2	CID000134141
Drug	K00077	STMN2 GRK2 GRK3 MYLK	2.47e-04	220	32	4	CID006419759
Drug	K 252	GRK2 GRK3 MYLK	2.55e-04	88	32	3	CID000003813
Drug	1,3-diolein	GRK2 GRK3 MYLK	2.73e-04	90	32	3	CID000033120
Drug	8-azido cyclic AMP	GRK2 GRK3	2.89e-04	18	32	2	CID000115296
Drug	isoquinolinium	GRK2 GRK3 MYLK	3.00e-04	93	32	3	CID000008405
Drug	3-(1H-pyrrole-2-carboxylate	GRK2 GRK3 MYLK PES1	3.07e-04	233	32	4	CID000005114
Drug	8-thiomethyl-cAMP	GRK2 GRK3	3.22e-04	19	32	2	CID000093140
Drug	8-azidoadenosine	GRK2 GRK3	3.22e-04	19	32	2	CID000160751
Drug	protocol C	LARS1 GAD2	3.58e-04	20	32	2	CID000015824
Drug	metoprolol	GRK2 GRK3 PES1	4.29e-04	105	32	3	CID000004171
Drug	Sp-8-Cl-cAMPS	GRK2 GRK3	4.34e-04	22	32	2	CID000133987
Drug	HA1004	GRK2 GRK3 MYLK	4.78e-04	109	32	3	CID000003546
Drug	SKF 38393	GAD2 GRK2 GRK3	4.91e-04	110	32	3	CID000001242
Drug	H-Tyr-Tic-Phe-Phe-OH	GAD2 GRK2	5.18e-04	24	32	2	CID000644210
Drug	1i9n	PLK4 OR1J2	5.63e-04	25	32	2	CID000446239
Drug	PDEs	GRK2 GRK3 MYLK	5.74e-04	116	32	3	CID003036959
Drug	SCH 23390	GAD2 GRK2 GRK3	5.74e-04	116	32	3	CID000005018
Drug	cyclizine	STMN2 GAD2 TCF7L1	5.74e-04	116	32	3	CID000006726
Drug	tyrphostin 23	GRK2 GRK3 MYLK	5.74e-04	116	32	3	CID000002052
Drug	7B-forskolin	GRK2 GRK3	6.09e-04	26	32	2	CID000130638
Drug	stacker	TCF7L2 TCF7L1	6.09e-04	26	32	2	CID000092326
Drug	amthamine	GRK2 GRK3	6.09e-04	26	32	2	CID000126688
Drug	amphetamine	GAD2 GRK2 GRK3 MYLK	6.47e-04	284	32	4	CID000003007
Drug	Kemptide	GRK2 GRK3 MYLK	6.97e-04	124	32	3	CID000100074
Drug	AC1O5WLA	GRK2 GRK3	8.12e-04	30	32	2	CID006442113
Drug	allylglycine	LARS1 GAD2	8.12e-04	30	32	2	CID000014044
Drug	AC1L1IZ2	GRK2 GRK3 MYLK PLK4	8.34e-04	304	32	4	CID000004795
Drug	K-13	GAD2 CPA3	8.68e-04	31	32	2	CID000469669
Drug	N6-monobutyryl-cAMP	GRK2 GRK3	9.83e-04	33	32	2	CID000115029
Drug	Adenosine triphosphate	GRK2 GRK3	9.83e-04	33	32	2	DB00171
Drug	V O2	LARS1 MYLK	9.83e-04	33	32	2	CID000082849
Drug	Ro 31	LARS1 GRK2 GRK3	1.01e-03	141	32	3	CID000214797
Drug	zaprinast	GRK2 GRK3 MYLK	1.01e-03	141	32	3	CID000005722
Drug	eg D	LARS1 GAD2	1.04e-03	34	32	2	CID000029544
Drug	NPLA	GRK2 GRK3	1.11e-03	35	32	2	CID000004387
Drug	Tannins	GRK2 GRK3	1.17e-03	36	32	2	CID000250395
Drug	fasudil	GRK2 GRK3 MYLK	1.23e-03	151	32	3	CID000003547
Drug	H-1152P	GRK2 MYLK PLK4	1.30e-03	154	32	3	CID000448043
Drug	Bolton-Hunter reagent	GRK2 GRK3	1.30e-03	38	32	2	CID000123813
Drug	AC1NR9P8	GRK2 GRK3	1.30e-03	38	32	2	CID005287445
Drug	CGS 15943	GRK2 GRK3	1.37e-03	39	32	2	CID000002690
Disease	gestational diabetes (is_implicated_in)	GAD2 TCF7L2	2.79e-05	8	30	2	DOID:11714 (is_implicated_in)
Disease	p-cresol sulfate measurement	STARD13 GAD2	1.19e-04	16	30	2	EFO_0010998
Disease	Parkinson's disease (biomarker_via_orthology)	GRK2 GRK3	4.27e-04	30	30	2	DOID:14330 (biomarker_via_orthology)
Disease	Adult Medulloblastoma	SCML2 PRAME	8.79e-04	43	30	2	C0278876
Disease	Childhood Medulloblastoma	SCML2 PRAME	8.79e-04	43	30	2	C0278510
Disease	Melanotic medulloblastoma	SCML2 PRAME	8.79e-04	43	30	2	C1275668
Disease	Medullomyoblastoma	SCML2 PRAME	8.79e-04	43	30	2	C0205833
Disease	Desmoplastic Medulloblastoma	SCML2 PRAME	8.79e-04	43	30	2	C0751291
Disease	Medulloblastoma	SCML2 PRAME	1.19e-03	50	30	2	C0025149
Disease	JT interval	GBF1 TASOR TCF7L1	2.01e-03	248	30	3	EFO_0007885
Disease	Manic Disorder	GAD2 GRK3	2.38e-03	71	30	2	C0024713
Disease	bipolar disorder, body mass index	TCF7L2 RIN2	2.44e-03	72	30	2	EFO_0004340, MONDO_0004985
Disease	Manic	GAD2 GRK3	2.86e-03	78	30	2	C0338831
Disease	Depression, Bipolar	GAD2 GRK3	2.93e-03	79	30	2	C0005587
Disease	congestive heart failure (is_marker_for)	GRK2 GRK3	3.16e-03	82	30	2	DOID:6000 (is_marker_for)
Disease	lymphocyte percentage of leukocytes	OSER1 GAD2 GBF1 TCF7L1	4.40e-03	665	30	4	EFO_0007993
Disease	coronary artery disease (is_implicated_in)	MYLK WRN	4.65e-03	100	30	2	DOID:3393 (is_implicated_in)
Disease	monocyte percentage of leukocytes	OSER1 GAD2 TCF7L2 AHNAK	6.14e-03	731	30	4	EFO_0007989

Protein segments in the cluster

Peptide	Gene	Start	Entry
MYAMKCLDKKRIKMK	GRK3	216	P35626
WHLKMPKMKMPKFSM	AHNAK	2506	Q09666
MTKYISKPENLKLMM	CAB39	246	Q9Y376
MKQKKMYKPEVSMKR	DIAPH2	626	O60879
MYAMKCLDKKRIKMK	GRK2	216	P25098
DIMKMLLMYCAKMEK	FEM1C	196	Q96JP0
MMIARFKMFPEVKEK	GAD2	251	Q05329
VTVPKMLMDMRTKYK	OR1J2	76	Q8NGS2
MKLSMKHQLPKMKTF	KANSL1L	261	A0AUZ9
MEAKKLSKDRMKKYM	MYLK	1726	Q15746
KDMKKAVAHMKYMGK	MATN2	716	O00339
FLMEMYKMKKPIMKA	MAGEB3	121	O15480
YKMKKPIMKADMLKI	MAGEB3	126	O15480
MKILKFMAKIYNKDP	MAGEE1	666	Q9HCI5
KMMDKYPEMVSRIKI	CPA3	131	P15088
RKKYMKAAEMGMPNK	CCP110	921	O43303
LKFQMEMYIKKLMEI	GBF1	491	Q92538
FMKRMKVPDYKDKAV	STARD13	646	Q9Y3M8
KKLKIFAMPMQDIKM	PRAME	211	P78395
LGSMPELKKYMKKVM	LARS1	976	Q9P2J5
ELKKYMKKVMPFVAM	LARS1	981	Q9P2J5
EKFRLYKLKMMAKME	WRN	886	Q14191
YKLKMMAKMEKYLHS	WRN	891	Q14191
DKKKFYVFGVAMTMM	SLC25A44	16	Q96H78
KMIDKKAMYKAGMVQ	PLK4	41	O00444
YLYIPKKMSHMAEMM	OSER1	276	Q9NX31
FKIMKGKIKSIYDPM	TASOR	241	Q9UK61
VEKIKVKFMTMQKMY	RIN2	651	Q8WYP3
VKFMTMQKMYSPEKK	RIN2	656	Q8WYP3
MQKMYSPEKKVMLLL	RIN2	661	Q8WYP3
SKAMVFMDVRMPKFK	VPS13A	751	Q96RL7
AIMMMKKREKYLYQK	PES1	536	O00541
VKKPLNAFMLYMKEM	TCF7L1	346	Q9HCS4
FLLKSDVMMKYMGLK	SCML2	666	Q9UQR0
KKPLNAFMLYMKEMR	TCF7L2	351	Q9NQB0
MAKTAMAYKEKMKEL	STMN2	1	Q93045
MAALEKMTFPKKMTF	ZRSR2P1	1	Q15695